Authors: Dubaquie, Y Mortensen, DL Intintoli, A Hogue, DA Nakamura, G Rancatore, P Lester, P Sadick, MD Filvaroff, E Fielder, PJ Lowman, HB

Citation: Y. Dubaquie et al., Binding protein-3-selective insulin-like growth factor I variants: Engineering, biodistributions, and clearance, ENDOCRINOL, 142(1), 2001, pp. 165-173

Authors: Nguyen, CB Szonyi, E Sadick, MD Hotaling, TE Mendoza-Ramirez, JL Escandon, E

Citation: Cb. Nguyen et al., Stability and interactions of recombinant human nerve growth factor in different biological matrices: In vitro and in vivo studies, DRUG META D, 28(5), 2000, pp. 590-597

Authors: Nguyen, CB Harris, L Szonyi, E Baughman, SA Hale, VG Dybdal, NO Sadick, MD Escandon, E

Citation: Cb. Nguyen et al., Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys, DRUG META D, 28(5), 2000, pp. 598-607

Authors: Sadick, MD Intintoli, A Quarmby, V McCoy, A Canova-Davis, E Ling, V

Citation: Md. Sadick et al., Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays, J PHARM B, 19(6), 1999, pp. 883-891